专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016011956A1 COMBINATION THERAPY 审中-公开
标题翻译：组合治疗
公开(公告)号：WO2016011956A1
公开(公告)日：2016-01-28
申请号：PCT/CN2015/084886
申请日：2015-07-23
申请人： NOVARTIS AG , HAO, Huaixiang , HUANG, Xizhong , MANENTI, Luigi , TAM, Angela
发明人： HAO, Huaixiang , HUANG, Xizhong , MANENTI, Luigi , TAM, Angela
IPC分类号： A61K31/4985 , A61K31/198 , A61K31/519 , A61K31/505 , A61P35/00
CPC分类号： A61K31/53 , A61K39/3955 , A61P35/00 , C07D487/04 , C07K16/2863 , A61K2300/00
摘要： The present disclosure relates to pharmaceutical products comprising a combination of (i) a MET inhibitor which is INC280 or a pharmaceutically acceptable salt or hydrate thereof and (ii) an EGFR inhibitor which is an monoclonal antibody such as cetuximab or panitumumab, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related embodiments.
摘要翻译：本公开内容涉及包含以下组合的药物产品：（i）INC280的MET抑制剂或其药学上可接受的盐或水合物和（ii）作为单克隆抗体如西妥昔单抗或帕尼单抗的EGFR抑制剂，其共同活性治疗增殖性疾病，相应的药物制剂，用途，方法，方法，商业包装和相关实施方案。

2. 发明申请

WO2016016822A1 COMBINATION THERAPY 审中-公开
标题翻译：组合治疗
公开(公告)号：WO2016016822A1
公开(公告)日：2016-02-04
申请号：PCT/IB2015/055737
申请日：2015-07-29
申请人： NOVARTIS AG , HAO, Huaixiang , HUANG, Xizhong , TAM, Angela , KASIBHATLA, Shailaja
发明人： HAO, Huaixiang , HUANG, Xizhong , TAM, Angela , KASIBHATLA, Shailaja
IPC分类号： C07D401/14 , A61K31/53 , A61K31/55 , C07D487/04 , A61P35/00
CPC分类号： A61K31/55 , A61K31/53 , C07D401/14 , C07D487/04 , A61K2300/00
摘要： The present disclosure relates to pharmaceutical products comprising a combination of (i) a MET inhibitor which is INC280 or a pharmaceutically acceptable salt or hydrate thereof and (ii) an EGFR inhibitor described herein, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related embodiments.
摘要翻译：本公开涉及包含以下组合的药物产品：（i）INC280的MET抑制剂或其药学上可接受的盐或水合物和（ii）本文所述的EGFR抑制剂，其共同地用于治疗增殖性疾病，相应的药物制剂，用途，方法，方法，商业包装和相关实施方案。

3. 发明申请

WO2012148846A1 COMBINATION OF A PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND A MTOR INHIBITOR 审中-公开
标题翻译：磷酸胆碱-3-激酶（PI3K）抑制剂和MT抑制剂的组合
公开(公告)号：WO2012148846A1
公开(公告)日：2012-11-01
申请号：PCT/US2012/034647
申请日：2012-04-23
申请人： NOVARTIS AG , FRITSCH, Christine , GARCIA-ECHEVERRIA, Carlos , HUANG, Xizhong , MAIRA, Sauveur-Michel
发明人： FRITSCH, Christine , GARCIA-ECHEVERRIA, Carlos , HUANG, Xizhong , MAIRA, Sauveur-Michel
IPC分类号： A61K31/436 , A61K31/4439 , A61P35/00
CPC分类号： A61K31/4439 , A61K31/427 , A61K31/436 , A61K31/439 , A61K31/506 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol- 3-kinase (PI3K) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mTOR) inhibitor or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising such a combination; and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mTOR) kinase dependent diseases.
摘要翻译：本发明涉及药物组合，其包含磷酰肌醇-3-激酶（PI3K）抑制剂化合物，其为2-甲酰胺环氨基脲衍生物或其药学上可接受的盐和至少一种哺乳动物雷帕霉素靶标（mTOR）抑制剂或药学上可接受的盐其可接受的盐; 包含这种组合的药物组合物; 以及这种组合在治疗增殖性疾病中的用途，更具体地涉及雷帕霉素（mTOR）激酶依赖性疾病的哺乳动物靶标。

4. 发明申请

WO2013148912A1 COMPOUNDS FOR USE IN THE TREATMENT OF NEUROBLASTOMA, EWING'S SARCOMA OR RHABDOMYOSARCOMA 审中-公开
标题翻译：用于治疗神经瘤的化合物，EWCOM的SARCOMA或RHABDOMYOSARCOMA
公开(公告)号：WO2013148912A1
公开(公告)日：2013-10-03
申请号：PCT/US2013/034214
申请日：2013-03-28
申请人： NOVARTIS AG , HUANG, Xizhong
发明人： HUANG, Xizhong
IPC分类号： A61K31/427 , A61K31/4439 , A61K31/497 , A61K31/506 , A61P35/00
CPC分类号： A61K31/4439 , A61K31/427 , A61K31/497 , A61K31/506
摘要： The present invention relates to a method of treating cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma comprising administering a therapeutically effective amount of a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof to a subject, preferably a human, in need thereof; to use of the compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for use in the treatment of cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma; and to use of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma.
摘要翻译：本发明涉及一种治疗选自神经母细胞瘤，尤因氏肉瘤或横纹肌肉瘤的癌症的方法，包括给予治疗有效量的如本文定义的式（I）化合物或其药学上可接受的盐至受试者，优选人;有需要的人; 使用式（I）化合物或其药学上可接受的盐来制备用于治疗选自神经母细胞瘤，尤因氏肉瘤或横纹肌肉瘤的癌症的药物组合物; 以及使用式（I）化合物或其药学上可接受的盐在治疗选自神经母细胞瘤，尤因氏肉瘤或横纹肌肉瘤的癌症中的用途。

5. 发明申请

WO2013053833A1 2 - CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES 审中-公开
标题翻译： 2 - 与用于治疗增殖性疾病的HSP90抑制剂组合的羧酰胺环磷酰脲类衍生物
公开(公告)号：WO2013053833A1
公开(公告)日：2013-04-18
申请号：PCT/EP2012/070171
申请日：2012-10-11
申请人： NOVARTIS AG , HUANG, Xizhong , QUADT, Cornelia , WANG, Hui-Qin , FRITSCH, Christine , SCHNELL, Christian René
发明人： HUANG, Xizhong , QUADT, Cornelia , WANG, Hui-Qin , FRITSCH, Christine , SCHNELL, Christian René
IPC分类号： A61K31/428 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K45/06 , A61K35/00
CPC分类号： A61K31/5377 , A61K31/16 , A61K31/235 , A61K31/428 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/52 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination comprising a 2-carboxamide cycloamino urea derivative compound of formula (I) and inhibitors of Heat Shock Protein 90, and the uses of such combinations in the treatment of proliferative diseases, more specifically PI3K dependent diseases, more specifically PI3K-alpha dependent diseases.
摘要翻译：本发明涉及包含式（I）的2-甲酰胺环氨基脲衍生物化合物和热休克蛋白90抑制剂的药物组合，以及这些组合在治疗增殖性疾病中的用途，更具体地说是PI3K依赖性疾病特别是PI3K-α依赖性疾病。

6. 发明申请

WO2014047109A1 PHARMACEUTICAL COMBINATION COMPRISING A PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR|AND AN AROMATASE INHIBITOR 审中-公开
标题翻译：包含磷脂酰肌氨酸3-激酶抑制剂的药物组合和芳香酶抑制剂
公开(公告)号：WO2014047109A1
公开(公告)日：2014-03-27
申请号：PCT/US2013/060292
申请日：2013-09-18
申请人： NOVARTIS AG , GOLDBRUNNER, Michael , HUANG, Xizhong
发明人： GOLDBRUNNER, Michael , HUANG, Xizhong
IPC分类号： A61K45/06 , A61K31/4184 , A61K31/4196 , A61K31/445 , A61K31/566 , A61K31/5685 , A61P35/00 , A61K31/4439
CPC分类号： A61K31/4439 , A61K31/4184 , A61K31/4196 , A61K31/445 , A61K31/566 , A61K31/5685 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination comprising a 2-carboxamide cycloamino urea derivative compound of formula (I) and at least one aromatase inhibitor for the treatment of cancer; the uses of such combinations in the treatment of cancer; and to a method of treating warm-blooded animals including humans suffering cancer by administering to said animal in need of such treatment an effective dose of a 2-carboxamide cycloamino urea derivative compound of formula (I) in combination with at least one aromatase inhibitor.
摘要翻译：本发明涉及包含式（I）的2-甲酰胺环氨基脲衍生物化合物和至少一种用于治疗癌症的芳香酶抑制剂的药物组合; 这些组合在治疗癌症中的用途; 以及通过向需要这种治疗的所述动物施用有效剂量的式（I）的2-甲酰胺环氨基脲衍生物化合物与至少一种芳香酶抑制剂组合来治疗包括患有癌症的人的温血动物的方法。

7. 发明申请

WO2013066483A1 SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS 审中-公开
标题翻译： PI3K和MEK-INHIBITORS的协同组合
公开(公告)号：WO2013066483A1
公开(公告)日：2013-05-10
申请号：PCT/US2012/052955
申请日：2012-08-30
申请人： NOVARTIS AG , FRITSCH, Christine , HUANG, Xizhong , BOEHM, Markus , DI TOMASO, Emmanuelle , COSAERT, Jan GCE
发明人： FRITSCH, Christine , HUANG, Xizhong , BOEHM, Markus , DI TOMASO, Emmanuelle , COSAERT, Jan GCE
IPC分类号： A61K31/4184 , A61K31/4412 , A61K31/4439 , A61K45/06 , A61P35/00 , A61P43/00
CPC分类号： A61K31/4439 , A61K31/4184 , A61K31/4412 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical combination comprising (a) the phosphatidylinositol 3-kinase (PI3K) inhibitor compound (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
摘要翻译：一种药物组合，其包含（a）磷脂酰肌醇3-激酶（PI3K）抑制剂化合物（S） - 吡咯烷-1,2-二羧酸2-酰胺1 - （{4-甲基-5- [2- 2-三氟-1,1-二甲基 - 乙基） - 吡啶-4-基] - 噻唑-2-基} - 酰胺）或其药学上可接受的盐，和（b）至少一种丝裂原活化蛋白激酶（MEK）抑制剂或药学上可接受的盐，以及任选的至少一种药学上可接受的载体，用于同时，分开或顺序施用; 这种组合在增殖性疾病治疗中的应用; 以及治疗患有增殖性疾病的受试者的方法，包括施用治疗有效量的这种组合。

8. 发明申请

WO2012047775A1 PHARMACEUTICAL COMBINATIONS 审中-公开
标题翻译：药物组合
公开(公告)号：WO2012047775A1
公开(公告)日：2012-04-12
申请号：PCT/US2011/054536
申请日：2011-10-03
申请人： NOVARTIS AG , CHEN, Yan , HUANG, Xizhong , MURPHY, Leon , NYFELER, Beat
发明人： CHEN, Yan , HUANG, Xizhong , MURPHY, Leon , NYFELER, Beat
IPC分类号： A61K31/4188 , A61K31/4745 , A61P35/00
CPC分类号： A61K31/436 , A61K31/4188 , A61K31/4745 , A61K31/496 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination which comprises (a) an mTOR catalytic inhibitor, such as a catalytic phosphatidylinositol- 3-kinase (PI3K) and mTOR inhibitor compound which is an imidazoquinoline derivative and (b) at least one allosteric mTOR inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of an mammalian target of rapamycin (mTOR) kinase dependent proliferative diseases; and the uses of such a combination in the treatment of mTOR kinase dependent proliferative diseases; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
摘要翻译：本发明涉及药物组合，其包含（a）mTOR催化抑制剂，例如催化磷脂酰肌醇-3-激酶（PI3K）和作为咪唑并喹啉衍生物的mTOR抑制剂化合物和（b）至少一种变构mTOR抑制剂化合物和任选的至少一种用于同时，分别或顺序使用的药学上可接受的载体，特别是用于治疗雷帕霉素（mTOR）激酶依赖性增殖性疾病的哺乳动物靶标; 以及这种组合在治疗mTOR激酶依赖性增殖性疾病中的应用; 包含这种组合的药物组合物; 使用这种组合来制备用于治疗增殖性疾病的药物; 商业包装或产品，其包含作为同时，分开或顺序使用的组合制剂的组合; 以及治疗温血动物，特别是人的方法。

9. 发明申请

WO2015022609A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：治疗癌症的联合治疗
公开(公告)号：WO2015022609A1
公开(公告)日：2015-02-19
申请号：PCT/IB2014/063782
申请日：2014-08-07
申请人： NOVARTIS AG , CHEN, Yan , HUANG, Xizhong , KIM, Sunkyu
发明人： CHEN, Yan , HUANG, Xizhong , KIM, Sunkyu
IPC分类号： A61K31/519 , A61K31/551 , A61P35/00
CPC分类号： A61K31/519 , A61K31/138 , A61K31/4196 , A61K31/436 , A61K31/4439 , A61K31/5377 , A61K31/551 , A61K31/5513 , A61K31/565 , A61K31/5685 , A61K45/06 , A61K2300/00
摘要： The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
摘要翻译：本公开涉及药物组合，其包含（1）作为CDK抑制剂或其药学上可接受的盐的第一药剂和（2）作为抗激素剂或其药学上可接受的盐的第二药剂。本公开还涉及药物组合，其包含（1）第一药剂，其为CDK抑制剂或其药学上可接受的盐，（2）第二药剂，其为抗激素剂或其药学上可接受的盐，和（ 3）作为调节PI3K / Akt / mTOR途径的药剂的第三药剂或其药学上可接受的盐。

10. 发明申请

WO2014028566A1 COMBINATION OF PI3K INHIBITOR AND C-MET INHIBITOR 审中-公开
标题翻译： PI3K抑制剂和C-MET抑制剂的组合
公开(公告)号：WO2014028566A1
公开(公告)日：2014-02-20
申请号：PCT/US2013/054848
申请日：2013-08-14
申请人： NOVARTIS AG , CAPONIGRO, Giordano , HUANG, Xizhong , LEHAR, Joseph , WANG, Hui-Qin
发明人： CAPONIGRO, Giordano , HUANG, Xizhong , LEHAR, Joseph , WANG, Hui-Qin
IPC分类号： A61K45/06 , A61K31/427 , A61K31/4745 , A61K31/5377 , A61P35/00
CPC分类号： A61K31/53 , A61K31/427 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.
摘要翻译：本发明涉及药物组合，其包含（a）磷脂酰肌醇3-激酶抑制剂或其药学上可接受的盐，和（b）至少一种c-Met受体酪氨酸激酶抑制剂或其药学上可接受的盐，用于同时，分别或顺序给药用于治疗增殖性疾病，特别是c-Met依赖性增殖性疾病; 包含这种组合的药物组合物; 一种治疗具有增殖性疾病的受试者的方法，包括向有需要的受试者施用所述组合; 使用这种组合治疗增殖性疾病; 以及包括这种组合的商业包装。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式